EMA/349760/2010

European Medicines Agency decision

P/119/2010

of 9 July 2010

on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo) (EMEA-000065-PIP01-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/119/2010

of 9 July 2010

on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine *(*Sebivo) (EMEA-000065-PIP01-07-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/111/2008 issued on 1 December 2008,

Having regard to the application submitted by Novartis Europharm Limited on 1 March 2010 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 May 2010, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for telbivudine (Sebivo), oral solution, film-coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, RH12 5AB Horsham, United Kingdom.

Done at London, 9 July 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/245345/2010

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000065-PIP01-07-M01

Scope of the application

Active substance(s):

Telbivudine

Invented name:

Sebivo

Condition(s):

Chronic Hepatitis B

Pharmaceutical form(s):

Oral solution

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 1 March 2010 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/111/2008 of 1 December 2008. The application for modification proposed changes.

The procedure started on 23 March 2010.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Scope of the modification

Some timelines of the original Opinion have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to the changes proposed by the applicant regarding the timelines of the paediatric investigation plan.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 21 May 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver

1. Condition(s)

Chronic hepatitis B

2. Waiver

2.1. Condition

Children with HBe-Antigen (HBeAg)-positive compensated chronic hepatitis B (CHB)

The waiver applies to:

- The paediatric population from birth to less than 2 years of age
- for Oral solution and Film-coated tablet, Oral use
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population

2.2. Condition

Children with HBeAg-negative compensated chronic hepatitis B

The waiver applies to:

- The paediatric population from birth to less than 2 years of age
- for Oral solution and Film-coated tablet, Oral use
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population

2.3. Condition

Children with decompensated chronic hepatitis B

The waiver applies to:

- The paediatric population from birth to less than 2 years of age
- for Oral solution and Film-coated tablet, Oral use
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population

2.4. Condition

Children with chronic hepatitis B in the immunotolerant phase

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age.
- for Oral solution and Film-coated tablet, Oral use
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population

3. Paediatric Investigation Plan

3.1. Condition to be investigated

Chronic hepatitis B

3.1.1. Indication targeted by the PIP

a. Treatment of children with HBeAg-positive compensated chronic hepatitis B

b. Treatment of children with HBeAg-negative compensated chronic hepatitis B

c. Treatment of children with decompensated chronic hepatitis B

3.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

3.1.3. Pharmaceutical form(s)

Film-coated tablet for oral use

Oral solution

3.1.4. Studies

Area	Number of studies	Description
Quality	1	Development of an age appropriate formulation for oral use
Non-clinical	2	• Study 1: A 20 days oral (gavage) neonatal and juvenile development dose range-finding study in rats • Study 2: A 10 weeks oral (gavage) study in juvenile rats to evaluate telbivudine effect on the postnatal development
Clinical	5	• Study 3: Open-Label, single-dose study in children and adolescents with Chronic Hepatitis B Virus Infection from 2 to less than 18 years of age to evaluate pharmacokinetics, safety and tolerability of telbivudine • Study 4: Randomised, double-blind, placebo-controlled, multi-centre study to evaluate pharmacokinetics, efficacy and safety of telbivudine in children and adolescents aged from 2 to less than 18 years with compensated HBeAg-positive chronic hepatitis B virus infection • Study 5: Randomised open label multi-centre study to evaluate efficacy and safety, of telbivudine in children and adolescents with compensated HBeAg-negative chronic hepatitis B virus infection in patients aged from 2 to less than 18 years • Study 6: Randomised open label multicenter study to evaluate

Area	Number of studies	Description
		efficacy and safety, of telbivudine in children and adolescents with decompensated chronic hepatitis B virus infection in patients aged from 2 to less than 18 years • Study 7: A cross-sectional, multi-center retrospective data collection study in Western and Asian countries in children and adolescents with chronic hepatits B virus infection in patients aged from 2-to less than18 year

4. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	**Yes**
Date of completion of the paediatric investigation plan:	By September 2018
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/07/388/001	Sebivo	600 mg	Film-coated tablet	Oral use	blister (PVC/alu)		28 tablets
EU/1/07/388/002	Sebivo	600 mg	Film-coated tablet	Oral use	blister (PVC/alu)		98 tablets
EU/1/07/388/003	Sebivo	20 mg/ml	Oral solution	Oral use	bottle (glass)	300 ml (20 mg/ml)	1 bottle + 1 cup + 1 oral syringe